You can buy or sell Kura Oncology and other stocks, options, ETFs, and crypto commission-free!
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. Read More The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
San Diego, California
52 Week High
52 Week Low
Research And Development
Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones
- Registration-directed trial of tipifarnib in HRAS mutant HNSCC continues on track - - Data from ongoing Phase 2 trial of tipifarnib in CXCL12-driven PTCL accepted for oral presentations at EHA and ICML next month - - Data from ongoing Phase 2 trial of tipifarnib in HRAS mutant HNSCC and other SCCs anticipated in second half 2019 - - $165.5 million in cash, cash equivalents and investments provide runway into 2021 - - Management to host webcast and conference call today at 4:30 p.m. ET - SAN DIE...
Expected Aug 5, After Hours